Royal DSM has announced a collaboration and commercialisation agreement with S-Biomedic. The collaboration aims to bring a new probiotic technology-based skin care active for the treatment of acne to market.
DSM will be S-Biomedic’s world-wide exclusive manufacturing & go-to-market partner for this active and plans to start commercialisation of the new technology within the next 18-24 months.
The microbiome is a strategic area for DSM. The company already holds a strong position in the field of gut health, with its range of probiotic solutions, and sees significant growth potential in probiotic skin care and other microbiome-focused solutions.
Recent studies into the skin microbiome reveal that skin-associated diseases such as acne vulgaris, eczema, psoriasis, and dandruff are associated with strong and specific changes within the microbiome. Researchers from S-Biomedic have been studying how live bacteria can be used to modulate the skin microbiome’s composition. "We observed better results using a multi-strain donor solution with recipient skin rich in a specific Cutibacterium acnes subtype, with positive features isolated from healthy individuals," explained Bernhard Paetzold, lead author of the study and co-founder and Chief Scientific Officer of S-Biomedic. These research findings open up vast opportunities for the development of probiotic solutions that could help improve microbiome status from diseased to healthy, specifically to treat inflammatory acne.
Under the terms of the agreement, DSM will contribute its manufacturing and commercialization expertise. “DSM has a proven track record in developing vitamins, yeast extracts, preservatives, cultures, biofuels, and bio-plastics via biotechnology,” commented Rishabh Pande, Vice President Marketing & Innovation, Personal Care & Aroma at DSM. “We have a solid manufacturing foundation to build on, and together with our strong expertise in distribution and marketing we look forward to bringing this exciting technology to the market”.
